CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Administration, Oral
Adult
Albumins
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Benzofurans
/ administration & dosage
Carcinoma, Pancreatic Ductal
/ drug therapy
Clinical Trials, Phase III as Topic
Deoxycytidine
/ administration & dosage
Drug Administration Schedule
Humans
Multicenter Studies as Topic
Naphthoquinones
/ administration & dosage
Paclitaxel
/ administration & dosage
Pancreatic Neoplasms
/ drug therapy
Progression-Free Survival
Randomized Controlled Trials as Topic
Young Adult
Gemcitabine
BBI-608
CanStem111P
cancer stem cells
napabucasin
pancreatic adenocarcinoma
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
16
2
2019
medline:
20
8
2019
entrez:
16
2
2019
Statut:
ppublish
Résumé
Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.
Identifiants
pubmed: 30768369
doi: 10.2217/fon-2018-0903
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Benzofurans
0
Naphthoquinones
0
napabucasin
0
Deoxycytidine
0W860991D6
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng